Deadline for Abstract Submission: February 28, 2017
Submit abstract utilizing the form below.
Categories for Poster Presentation:
- Pathogenesis of Spondyloarthritis
- Imaging in Spondyloarthritis
- Clinical Research in Spondyloarthritis
Trainees with the highest ranked abstracts may be invited to present their work in a short oral session (5 minutes presentation and 2 minutes for questions).
Oral Presentation Abstracts:
SPARTAN is encouraging translational research as a means of improving our understanding of the cause and for identification of novel therapeutic targets in Spondyloarthritis. Abstracts presented in this category will be considered for oral presentations at the annual meeting. If your abstract is not selected for oral presentation, it will be transferred to the poster session under the category ‘pathogenesis of SpA’.
Reviewers selected by the Scientific Committee will score abstracts for oral and poster presentations.
Abstracts should not be already published as a manuscript. Relevant abstracts presented at meetings within a year are eligible for submission. Abstracts submitted to this year’s SPARTAN meeting are also eligible for submission to the ACR Annual Scientific meeting (submission deadline in late June for presentation in November).
Abstract Processing fee:
There is no processing fee to have your abstract considered.
Abstracts may be selected for oral or poster presentation, and authors should be prepared to present in either format. The abstract limit is 2,750 characters, which excludes the title, names of authors/co-authors, authors’ affiliations, spacing and disclosures. Each tables and/ or graphic will decrease the character count by 250 characters from the total limit allowed. A maximum of 3 figures/tables are allowed per abstract. The Translational Research Oral Abstract Showcase will include 10 minute presentations followed by 5 minutes of questions and comments. The short oral presentations for selected poster abstracts will include 5 minute presentations followed by 2 minutes of questions and comments.
- Titles should be brief, indicating the nature of the presentation. Use mixed case (do not use all caps) and do not put a period at the end of the title. Example: This is a Properly Formatted Abstract Title
- Use of acronyms Please refrain from using acronyms in your abstract titles. Acronyms may remain in the body of the abstract and in the author list.
- Authors: Please consult with your co-authors on how they would like their names to appear. There is no limit on number of authors for each abstract. All authors must disclose any relevant financial relationship(s) at the time of abstract submission.
- Content: Organize content as follows:
- Background: Background or Statement of Purpose
- Methods: Methods, materials and analytical procedure used
- Results: Summary of the results in sufficient detail to support conclusion
- Conclusion: Conclusions reached (do not state “results will be discussed”).
- Use of Product Names: The generic name should be used in your abstract. The proprietary drug name may appear once in parentheses in the title only. However, if a drug has not received FDA approval, only the non-proprietary name may be used in the title and abstract content.
- Abbreviations: Place abbreviations in parentheses after the first time the full word appears. Do not abbreviate compounds in the title of the abstract. Use numerals to indicate numbers, except when beginning sentences.
Any work with human or animal subjects reported in submitted abstracts must comply with the guiding principles for experimental procedures found in the Declaration of Helsinki of the World Medical Association.
Fellows with accepted abstracts will be provided a travel award to attend the annual meeting, which covers an airline ticket and hotel accommodations.